FTC challenges Illumina’s purchase of cancer test manufacturer
Illumina’s proposed $8 billion acquisition of Grail could give it sole control over the market for certain cancer-screening tests, the Federal Trade Commission has alleged in a lawsuit seeking to block the merger.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10